Subscribe to RSS
DOI: 10.1055/a-2693-1815
LINAC-based Stereotactic Radiotherapy for Acromegaly: A Single-center Retrospective Cohort
Funding Information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Our Radiation Oncology Department was granted by the Technical Cooperation Program from the International Atomic Energy Agency (IAEA) funds for renovation of the radiosurgery planning and delivery system in 2010.

Abstract
Background
Most results for stereotactic radiotherapy (SRT) for acromegaly patients come from Gamma-Knife series. We aim to describe outcomes for LINAC-based SRT, as well as compare results for single-dose (SRS) and fractionated (SFRT) treatments.
Methods
Single-center retrospective cohort in a tertiary, academic hospital assessed between 2008 and 2024.
Results
A total of 48 patients were assessed for outcomes of acromegaly after SRT. Most of them female (62.5%). Mean age was 42.5 years (range 12–73). Median lesion size was 2.1 cm (range 0.2 to 7.2 cm). Among previous deficits, previous hormonal deficits (31.3%) and visual deficits (45.8%) were common. Most patients were diagnosed with pure somatotrophic lesions (87.5%). SRS was done in 16 (33.3%) patients and 32 (66.7%) underwent SFRT. Concurrent octreotide long-acting release (Oct-LAR) (29/60.4%) and cabergoline (20/41.7%) were also common. Median follow-up was 85.3 months (8.2–187.9 months). Tumor control was achieved in 47 (97.9%). Mean progression-free survival (PFS) was 85.3 months (92.4 months for SRS and 81.7 months for SFRT, p = 0.42). Univariate analysis showed no variable impacted overall survival (OS), PFS, new visual, or new hormonal disorders. Hormonal remission was achieved in 22 (45.8%) patients. Median time to hormonal disease control (THC) was 73.1 months for the entire cohort, and 45.8 months for SRS patients and 74.7 months for SFRT patients, with no difference between groups ([HR], 0.30; 95% CI, −1.14 to 0.53; p = 0.47).
Conclusion
We described acromegaly patients treated with LINAC SRS and with the current criteria for hormonal cure. THC was longer for SFRT patients, with no statistical differences. Concurrent treatment did not impact outcomes.
Contributors' Statement
G.M. and L.d.R.: responsible for study design; L.d.R.: responsible for ethics committee approval; G.M. and V.G.: responsible for data collection; G.M. and S.V.: wrote the project's final draft; G.M.: responsible for statistical analysis; E.W., E.S., R.J., M.N., and R.V.: responsible for overall orientation and manuscript review.
Data Availability Statement
Data on this research is available on request to the corresponding author.
Ethical Approval
According to the Brazilian law and the Declaration of Helsinki, ethics committee authorization was obtained from the local ethics committee. Due to its retrospective nature, the local ethics committee allowed this research to be conducted without signed patient consent.
Informed Consent
The authors grant the publisher the sole and exclusive license of the full copyright. The authors guarantee that this manuscript has not been previously published elsewhere. The authors declare that any person named as co-author of the contribution is aware of the fact and has agreed to being so named.
Dedication
We dedicate this paper to the work of Dr. Nina Rosa de Castro Musolino (in memoriam).
Publication History
Received: 13 June 2025
Accepted: 29 August 2025
Article published online:
09 September 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Mathieu D, Kotecha R, Sahgal A. et al. Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations. J Neurosurg 2021; 136 (03) 801-812
- 2 Singh R, Didwania P, Lehrer EJ. et al. Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes. J Neurooncol 2020; 148 (03) 401-418
- 3 Maroufi SF, Assar M, Khorasanizadeh M. et al. Assessment of multimodal treatment options in recurrent and persistent acromegaly: a systematic review and meta-analysis. J Neurooncol 2024; 168 (01) 13-25
- 4 Wan H, Chihiro O, Yuan S. MASEP gamma knife radiosurgery for secretory pituitary adenomas: experience in 347 consecutive cases. J Exp Clin Cancer Res 2009; 28 (01) 36
- 5 Giustina A, Biermasz N, Casanueva FF. et al; Acromegaly Consensus Group. Consensus on criteria for acromegaly diagnosis and remission. Pituitary 2024; 27 (01) 7-22
- 6 Schwartz LH, Seymour L, Litière S. et al. RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer 2016; 62: 138-145
- 7 Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Hypopituitarism. Lancet 2024; 403 (10444): 2632-2648
- 8 Lloyd RV, Osamura R, Rosai J. WHO Classification of tumours editorial board: endocrine and neuroendocrine tumours. International agency for research on cancer; Lyon, France: 2022
- 9 Jagannathan J, Yen CP, Pouratian N, Laws ER, Sheehan JP. Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife. J Neurooncol 2009; 92 (03) 345-356
- 10 Jezková J, Marek J, Hána V. et al. Gamma knife radiosurgery for acromegaly—long-term experience. Clin Endocrinol (Oxf) 2006; 64 (05) 588-595
- 11 Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R. Failure of radiotherapy in acromegaly. Eur J Endocrinol 2001; 145 (06) 717-726
- 12 Deshmukh H, Ssemmondo E, Adeleke K. et al; UK Acromegaly Register Study (UKAR) Group. Time to first remission and survival in patients with acromegaly: evidence from the UK Acromegaly Register Study (UKAR). Clin Endocrinol (Oxf) 2024; 101 (03) 274-281
- 13 Franzin A, Spatola G, Losa M, Picozzi P, Mortini P. Results of gamma knife radiosurgery in acromegaly. Int J Endocrinol 2012; 2012 (01) 342034
- 14 Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 2011; 114 (02) 303-309
- 15 Ding D, Mehta GU, Patibandla MR. et al. Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study. Neurosurgery 2019; 84 (03) 717-725
- 16 Romero-Gameros CA, González-Virla B, Vargas-Ortega G. et al. Efficiency and safety of CyberKnife robotic radiosurgery in the multimodal management of patients with acromegaly. Cancers (Basel) 2023; 15 (05) 1438
- 17 Pai FY, Chen CJ, Wang WH. et al. Low-dose gamma knife radiosurgery for acromegaly. Neurosurgery 2019; 85 (01) E20-E30
- 18 Vik-Mo EO, Øksnes M, Pedersen PH. et al. Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 2007; 157 (03) 255-263
- 19 Meral R, Selcukbiricik OS, Uzum AK. et al. Promising outcomes in acromegaly patients receiving cyberknife stereotactic hypofractionated radiotherapy. Cureus 2023; 15 (10) e47936
- 20 Sala E, Moore JM, Amorin A. et al. CyberKnife robotic radiosurgery in the multimodal management of acromegaly patients with invasive macroadenoma: a single center's experience. J Neurooncol 2018; 138 (02) 291-298
- 21 Roberts BK, Ouyang DL, Lad SP. et al. Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 2007; 10 (01) 19-25
- 22 Liu X, Kano H, Kondziolka D. et al. Gamma knife radiosurgery for clinically persistent acromegaly. J Neurooncol 2012; 109 (01) 71-79
- 23 Trifiletti DM, Xu Z, Dutta SW. et al. Endocrine remission after pituitary stereotactic radiosurgery: differences in rates of response for matched cohorts of Cushing disease and acromegaly patients. Int J Radiat Oncol Biol Phys 2018; 101 (03) 610-617
- 24 Škorić Polovina T, Režić T, Kraljević I. et al; CRO-ACRO Study Group. Gamma-knife radiosurgery in acromegaly: the results from the Croatian acromegaly registry. Br J Neurosurg 2024; 38 (04) 833-837
- 25 Lee CC, Vance ML, Xu Z. et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 2014; 99 (04) 1273-1281
- 26 Patibandla MR, Xu Z, Sheehan JP. Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery. J Neurooncol 2018; 138 (01) 209-216
- 27 Iwata H, Sato K, Nomura R. et al. Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus. J Neurooncol 2016; 128 (02) 267-275
- 28 Uygur MM, Deyneli O, Yavuz DG. Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients. Growth Horm IGF Res 2020; 55: 101335
- 29 Rhome R, Germano IM, Sheu RD, Green S. Long-term outcomes of acromegaly treated with fractionated stereotactic radiation: case series and literature review. Neurooncol Pract 2017; 4 (04) 255-262
- 30 Wilson PJ, De-Loyde KJ, Williams JR, Smee RI. Acromegaly: a single centre's experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator. J Clin Neurosci 2013; 20 (11) 1506-1513
- 31 Knappe UJ, Petroff D, Quinkler M. et al; participants of the German Acromegaly Registry. Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. Eur J Endocrinol 2020; 182 (03) 275-284
- 32 Arnardóttir S, Järås J, Burman P. et al. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur J Endocrinol 2022; 186 (03) 329-339
- 33 Zheng Q, Huang Y, Lin W, Cai L, Wen J, Chen G. Comparing stereotactic radiosurgery and fractionated stereotactic radiotherapy in treating patients with growth hormone-secreting adenomas: a systematic review and meta-analysis. Endocr Pract 2020; . Epub ahead of print
- 34 Landolt AM, Haller D, Lomax N. et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88 (06) 1002-1008
- 35 Gonzales-Virla B, Vargas-Ortega G, Martínez-Vázquez KB. et al. Efficacy and safety of fractionated conformal radiation therapy in acromegaly: a long-term follow-up study. Endocrine 2019; 65 (02) 386-392
- 36 Gheorghiu ML, Fleseriu M. Stereotactic radiation therapy in pituitary adenomas, is it better than conventional radiation therapy?. Acta Endocrinol (Bucur) 2017; 13 (04) 476-490
- 37 Lian X, Shen J, Gu Z. et al. Intensity-modulated radiotherapy for pituitary somatotroph adenomas. J Clin Endocrinol Metab 2020; 105 (12) e4712-e4721
- 38 Cordeiro D, Xu Z, Mehta GU. et al. Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study. J Neurosurg 2018; 131 (04) 1188-1196
- 39 Castinetti F, Taieb D, Kuhn JM. et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005; 90 (08) 4483-4488
- 40 Urwyler SA, Samperi I, Lithgow K. et al. Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur J Endocrinol 2024; 190 (01) 113-120
- 41 Alquraini H, Del Pilar Schneider M, Mirakhur B, Barkan A. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials. Pituitary 2018; 21 (03) 283-289